Menu
Search
|

Menu

Close
X

Aileron Therapeutics Inc ALRN.OQ (NASDAQ Stock Exchange Global Market)

0.57 USD
-0.03 (-5.00%)
As of 4:00 PM EDT
Previous Close 0.60
Open 0.57
Volume 39,490
3m Avg Volume 48,497
Today’s High 0.60
Today’s Low 0.56
52 Week High 5.14
52 Week Low 0.52
Shares Outstanding (mil) 26.71
Market Capitalization (mil) 16.03
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-0.487
FY18
-2.141
FY17
-1.539
FY16
-1.237
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.23
Price to Sales (TTM)
vs sector
--
10.86
Price to Book (MRQ)
vs sector
0.69
4.40
Price to Cash Flow (TTM)
vs sector
--
24.08
Total Debt to Equity (MRQ)
vs sector
0.00
18.12
LT Debt to Equity (MRQ)
vs sector
0.00
12.99
Return on Investment (TTM)
vs sector
-106.12
12.65
Return on Equity (TTM)
vs sector
-115.83
17.19

EXECUTIVE LEADERSHIP

Jeffrey Bailey
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Manuel Aivado
President, Chief Executive Officer, Director, Since 2018
Salary: $391,065.00
Bonus: $140,000.00
Donald Dougherty
Senior Vice President, Chief Financial Officer, Since 2017
Salary: $194,072.00
Bonus: $105,500.00
D. Allen Annis
Senior Vice President - Research, Since 2018
Salary: --
Bonus: --
Kira Nelson
Vice President - Finance, Vice President - Operations, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

490 Arsenal Way
WATERTOWN   MA   02472-2870

Phone: +1617.9950900

Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.

SPONSORED STORIES